Article
Comparative evaluation of synthetic cytokines for enhancing production and performance of NK92 cell-based therapies
2023-05-14
Abstract excerpt
Autologous immune cell therapies are potentially curative, but cost and manufacturing complexity limit access. Off-the-shelf therapies may address these gaps, but further development is needed. The NK92 cell line has a natural killer-like phenotype, has efficacy in cancer clinical trials, and is safe after irradiation. However, NK92 lose activity post-injection, limiting efficacy. This may be addressed by engineer...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 976c1e72-eedf-56fb-8b68-0726df9dcf56
- DOI
- 10.1101/2023.05.13.540611
